US20010020087A1 - Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom - Google Patents

Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom Download PDF

Info

Publication number
US20010020087A1
US20010020087A1 US09/805,760 US80576001A US2001020087A1 US 20010020087 A1 US20010020087 A1 US 20010020087A1 US 80576001 A US80576001 A US 80576001A US 2001020087 A1 US2001020087 A1 US 2001020087A1
Authority
US
United States
Prior art keywords
methyl
oxo
ethyl
isopropyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/805,760
Inventor
Rosie Wong
Joseph Pont
Alvin Crews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US09/805,760 priority Critical patent/US20010020087A1/en
Publication of US20010020087A1 publication Critical patent/US20010020087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Definitions

  • imidazolinone compounds have given new meaning to the term “weed control”; for within this series of compounds it has been found that some are broad-spectrum or total vegetation herbicides with activity in both herbaceous and woody plants while others are highly selective weed control agents useful in the presence of crops.
  • the imidazolinones are best exemplified by the commercial compounds imazethapyr, imazaquin, imazamethabenz-methyl and imazapyr.
  • Imidazolinone compounds are used by farmers throughout the world to control undesirable plant species. In certain areas, several imidazolinone compounds are individually used to control weeds growing in the presence of different crops such as soybeans, corn, peanuts, wheat, barley, rye and sunflowers, among others.
  • imidazolinone compounds gradually degrade in the environment, residues remaining in the soil should be monitored so as to provide the most efficacious weed control while avoiding possible damage to follow crop plants. It is particularly important to monitor individual imidazolinone residues in those areas where several imidazolinones are used.
  • the present invention provides imidazolinone haptens and antigens and enzyme conjugates which are prepared from the imidazolinone haptens.
  • the antigens of the present invention are used to prepare imidazolinone specific monoclonal antibodies.
  • certain of those monoclonal antibodies are used to determine the presence and concentration of an imidazolinone compound in the presence of one or more other imidazolinone compounds.
  • the enzyme conjugates of the present invention are used in a direct competition immunoassay to determine the presence and concentration of an imidazolinone compound.
  • the present invention provides imidazolinone haptens that are used to prepare antigens which elicit imidazolinone specific antibody production in animals.
  • the imidazolinone haptens of the present invention have the structural formula
  • R is hydrogen or C 1 -C 4 alkyl
  • R 1 is C 1 -C 4 alkyl
  • R 2 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; and when R 1 and R 2 are taken together with the carbon atom to which they are attached they may represent C 3 -C 6 cycloalkyl optionally substituted with methyl;
  • Y and Z are each independently hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 4 alkoxyalkyl, C 1 -C 4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, phenoxy, C 1 -C 4 halo-alkyl, nitro, cyano, C 1 -C 4 alkylamino, di(C 1 -C 4 alkyl)amino, C 1 -C 4 alkylsulfonyl or phenyl optionally substituted with one C 1 -C 4 alkyl group, C 1 -C 4 alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH 2 ) n -, where n is an integer of 3 or 4; or
  • R 3 , R 4 , R 5 and R 6 are each independently hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • A is N or CH
  • W is C 3 -C 12 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C 3 -C 12 alkenylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C 3 -C 12 alkynylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom; and
  • W 1 is C l -C 12 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C 2 -C 12 alkenylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C 3 -C 12 alkynylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom.
  • Preferred formula I and II haptens are those wherein
  • R is hydrogen or methyl
  • R 1 is methyl
  • R 2 is isopropyl
  • Y is hydrogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxyalkyl
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH ⁇ CH—CH ⁇ CH—;
  • A is N or CH
  • W is C 3 -C 12 alkylene or C 3 -C 12 alkenylene
  • W 1 is C 1 -C 12 alkylene or C 2 -C 12 alkenylene.
  • More preferred formula I and II haptens which are used to prepare antigens which elicit imidazolinone specific antibody production in animals are those wherein
  • R is hydrogen or methyl
  • R 1 is methyl
  • R 2 is isopropyl
  • Y is hydrogen, methyl, ethyl or methoxymethyl
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH ⁇ CH—CH ⁇ CH—;
  • A is N;
  • W is C 3 -C 6 alkylene or C 3 -C 6 alkenylene
  • W 1 is C 1 -C 6 alkylene or C 2 -C 6 alkenylene.
  • Imidazolinone haptens of the present invention which are particularly useful in the preparation of antigens include
  • antigens of the present invention which are prepared from the imidazolinone haptens described above and are useful in the production of imidazolinone specific antibodies in animals have the structural formula
  • R is hydrogen or C 1 -C 4 alkyl
  • R 1 is C 1 -C 4 alkyl
  • R 2 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; and when R 1 and R 2 are taken together with the carbon atom to which they are attached they may represent C 3 -C 6 cycloalkyl optionally substituted with methyl;
  • Y and Z are each independently hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 4 alkoxyalkyl, C 1 -C 4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, phenoxy, C 1 -C 4 halo-alkyl, nitro, cyano, C 1 -C 4 alkylamino, di(C 1 -C 4 alkylamino, C 1 -C 4 alkylsulfonyl or phenyl optionally substituted with one C 1 -C 4 alkyl group, C 1 -C 4 alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH 2 ) n -, where n is an integer of 3 or 4; or
  • R 3 , R 4 , R 5 and R 6 are each independently hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • A is N or CH
  • W is C 3 -C 12 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C 3 -C 12 alkenylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C 3 -C 12 alkynylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom;
  • W 1 is C 1 -C 12 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C 2 -C 12 alkenylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C 3 -C 12 alkynylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom;
  • X is an integer from about 1 to 40.
  • Q is a protein
  • Proteins suitable for use in the antigens of this invention include cationized bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, bovine serum albumin, thyroglobulin, human serum albumin, fibrinogen and the like.
  • Preferred formula III and IV antigens of the present invention are those wherein
  • R is hydrogen or methyl
  • R 1 is methyl
  • R 2 is isopropyl
  • Y is hydrogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxyalkyl
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH ⁇ CH—CH ⁇ CH—;
  • A is N or CH
  • W is C 3 -C 12 alkylene or C 3 -C 12 alkenylene
  • W 1 is C 1 -C 12 alkylene or C 2 -C 12 alkenylene
  • X is an integer from about 1 to 40;
  • Q is a protein
  • R is hydrogen or methyl
  • R 1 is methyl
  • R 2 is isopropyl
  • Y is hydrogen, methyl, ethyl or methoxymethyl
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH ⁇ CH—CH ⁇ CH—;
  • A is N;
  • W is C 3 -C 6 alkylene or C 3 -C 6 alkenylene
  • W 1 is C 1 -C 6 alkylene or C 2 -C 6 alkenylene
  • X is an integer from about 1 to 40;
  • Q is a protein
  • Antigens of the present invention which are especially useful in the production of imidazolinone specific antibodies are those having the following structural formula
  • X is an integer from about 1 to 40;
  • OVA is ovalbumin
  • Q is keyhole limpet hemocyanin or cationized bovine serum albumin.
  • the present invention further provides enzyme conjugates which are used in a direct competition immuno-assay to determine the presence of imidazolinone compounds in water, soil or plant samples.
  • R is hydrogen or C 1 -C 4 alkyl
  • R 1 is C 1 -C 4 alkyl
  • R 2 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; and when R 1 and R 2 are taken together with the carbon atom to which they are attached they may represent C 3 -C 6 cycloalkyl optionally substituted with methyl;
  • Y and Z are each independently hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 4 alkoxyalkyl, C 1 -C 4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, phenoxy, C 1 -C 4 halo-alkyl, nitro, cyano, C 1 -C 4 alkylamino, di(C 1 -C 4 alkyl)amino, C 1 -C 4 alkylsulfonyl or phenyl optionally substituted with one C 1 -C 4 alkyl group, C 1 -C 4 alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH 2 ) n -, where n is an integer of 3 or 4; or
  • R 3 , R 4 , R 5 and R 6 are each independently hydrogen, halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • A is N or CH
  • W is C 3 -C 12 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C 3 -C 12 alkenylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C 3 -C 12 alkynylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom;
  • W 1 is C 1 -C 12 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C 2 -C 12 alkenylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C 3 -C 12 alkynylene optionally substituted with one or two C 1 -C 3 alkyl groups, C 1 -C 3 alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom; and
  • E is an enzyme
  • Enzymes suitable for use in the enzyme conjugates of the present invention include those that produce a color change when treated with a substrate.
  • Preferred enzymes are alkaline phosphatase, horseradish peroxidase, urease, glucose oxidase and galactosidase.
  • Preferred formula VIII and IX enzyme conjugates are those wherein
  • R is hydrogen or methyl
  • R 1 is methyl
  • R 2 is isopropyl
  • Y is hydrogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxyalkyl
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH ⁇ CH—CH ⁇ CH—;
  • A is N or CH
  • W is C 3 -C 12 alkylene or C 3 -C 12 alkenylene
  • W 1 is C 1 -C 12 alkylene or C 2 -C 12 alkenylene
  • E is an enzyme
  • R is hydrogen or methyl
  • R 1 is methyl
  • R 2 is isopropyl
  • Y is hydrogen, methyl, ethyl or methoxymethyl
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH ⁇ CH—CH ⁇ CH—;
  • A is N;
  • W is C 3 -C 6 alkylene or C 3 -C 6 alkenylene
  • W 1 is C 1 -C 6 alkylene or C 2 -C 6 alkenylene
  • E is an enzyme
  • One of the most preferred enzyme conjugates of this invention has the following structural formula
  • E is alkaline phosphatase.
  • the formula I haptens of the present invention may be prepared by reacting a compound having the structural formula XI
  • R and W are as described hereinabove; and the acid addition salts thereof in the presence of a trialkylamine such as triethylamine and a polar solvent such as N,N-dimethylformamide to form a reaction mixture which is quenched with aqueous acid to form the desired formula I hapten.
  • a trialkylamine such as triethylamine
  • a polar solvent such as N,N-dimethylformamide
  • formula I haptens may be prepared by reacting a compound having the structural formula XI with an amino acid ester having the structural formula XIII
  • R 7 is C 1 -C 4 alkyl
  • Formula II haptens may be prepared by reacting a compound having the structural formula XV
  • W 1 and R 7 are as described hereinabove; and X 1 is halogen to form a compound having the structural formula XVII
  • the antigens of the present invention may be prepared by reacting a hapten of the present invention with at least about one molar equivalent of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride to form an activated hapten and reacting the activated hapten with the amino groups of a protein to form the desired antigen.
  • the above reaction scheme is shown in Flow Diagrams IV(a) and IV(b).
  • the enzyme conjugates of the present invention may be prepared as shown below in Flow Diagrams V(a) and V(b).
  • the antigens of the present invention are used to elicit imidazolinone specific antibody production in animals. Several weeks after an animal is immunized with one or more antigens, the serum is harvested and the polyclonal antibodies present in the serum may be used in indirect or direct immunoassays to determine the presence and quantity of imidazolinone compounds in soil, water or plant samples.
  • certain hybridomas prepared by fusing a spleen cell from an animal immunized with an antigen of the present invention with a myeloma cell, produce monoclonal antibodies which are specific for one imidazolinone compound among others.
  • imidazolinone antibodies were not specific enough to allow for the accurate determination of the presence and quantity of an imidazolinone compound in the presence of one or more other imidazolinone compounds.
  • the methods used to prepare the polyclonal antibodies, hybridomas and monoclonal antibodies of the present invention are described in the examples. Also described in the examples are the indirect and direct immunoassay methods which are used to determine the presence and quantity of an imidazolinone compound present in a sample.
  • the imidazolinone compounds are represented by structural formula XVIII
  • Y, Z, A, R 1 and R 2 are as described hereinabove;
  • R 8 is hydrogen or C 1 -C 4 alkyl.
  • polyclonal and monoclonal antibodies of this invention are especially useful in indirect and direct immunoassays to determine the presence and quantity of the following imidazolinone compounds:
  • a stirred suspension of sodium hydride (1.6 g, 53 mmol, 80% oil dispersion) in dry tetrahydrofuran is treated with a solution of 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline (10.24 g, 41.80 mmol) in dry tetrahydrofuran dropwise via addition funnel.
  • 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline 10.24 g, 41.80 mmol
  • ethyl 4-bromocrotonate (12.9 g, 50.1 mmol, 75% technical grade) is added to the reaction mixture at once. The resulting mixture is stirred at room temperature under nitrogen for 19 hours.
  • reaction mixture is partitioned between water and ether.
  • the layers are separated, and the organic layer is dried over magnesium sulfate, decolorized with activated charcoal, vacuum filtered through diatomaceous earth, and concentrated in vacuo to obtain a dark brown oil.
  • the oil is purified by flash chromatography (2:1 hexanes/ethyl acetate eluent) to give the title product as a pale orange oil (3.78 g, 25%).
  • the layers are separated, and the organic layer is dried over magnesium sulfate, vacuum filtered through diatomaceous earth and concentrated in vacuo to obtain a residue.
  • the residue is purified by flash chromatography (2:1 hexanes/ethyl acetate eluent) to give the title product as a pale yellow oil.
  • the mixture containing the activated hapten is added to a solution of keyhole limpet hemocyanin (KLH, 10 mg, 22 nmol) in alkaline aqueous buffer (pH 7.2-7.6).
  • KLH keyhole limpet hemocyanin
  • the final molar ratio of hapten to total protein amino groups is greater than 100 to 1.
  • the reaction mixture is stirred for 2 hours at room temperature and passed through molecular sieving columns to remove excess reagents.
  • the antigen fraction is filtered through a 0.22 ⁇ filter and stored at 4° C.
  • Flow Diagram VI illustrates the above reactions.
  • KLH is keyhole limpet hemocyanin.
  • X is an integer from about 1 to 40;
  • cBSA is cationized bovine serum albumin
  • OVA is ovalbumin
  • KLH is keyhole limpet hemocyanin.
  • mice of the Swiss Webster and Biozzi strains are immunized with antigens A, B, D and E, prepared in Example 8.
  • the initial doses consist of 50 ⁇ g of antigen in 0.1 mL of physiological saline and one mouse dose (about 50 ⁇ g) of Ribi adjuvant (“MPL+TDM Emulsion,” Ribi Immunochem Research, Hamilton, Mont.).
  • Booster doses are given 7 and 22 days after the first dose and consist of 25 ⁇ g of antigen in saline with Ribi adjuvant.
  • Immunizations are subcutaneous, in 3 or 4 sites on the back of the mouse. Sera are taken on the twenty-ninth day after the first injection. Titers are determined by indirect enzyme immunoassay and then analyzed for ability to bind free imidazolinones in an indirect competition enzyme immunoassay as described below.
  • An indirect enzyme immunoassay is used to screen for the production of anti-imidazolinone antibodies in the serum of the immunized mice and in cell fusion cultures.
  • the method used is essentially the same as the method described by Voller, et al (Manual of Clinical Immunology, eds. N. Rose Friedman, H., pp. 506-512, 1976).
  • an antigen is adsorbed onto polystyrene flat bottom wells in 0.1 M Na 2 CO 3 buffer pH 9.6.
  • the best responding Swiss Webster mouse is “hyperimmunized” by intravenous injection of 50 ⁇ g of antigen in saline, 4 days prior to cell fusion which is about 60 days after the first immunization.
  • the hybridomas are prepared by fusing spleen cells from the mouse with P3X63AG8.653 myeloma cells by electrofusion.
  • the reagent buffers and cell culture media used are essentially the same as described by B. Forghani and A. E. Karu, Virology LabFAX, eds. DR Harper, pp. 187-214, Oxford: Bios Scientific Publishers Ltd., 1993.
  • the electrofusion is performed as described by A. E. Karu et al, Journal of Agricultural and Food Chemistry, 42, pp. 301-309, 1994.
  • reaction mixture After stirring for 3.5 hours, the reaction mixture is slowly added to an alkaline phosphatase solution in 0.05 M sodium borate buffer pH 7.5 with 0.9% NaCl. The resultant mixture is stirred at 4° C. for 18 hours and passed through an agarose column to give an enzyme conjugate having the structural formula shown below.
  • E alkaline phosphatase
  • BRL alkaline phosphatase substrate amplification kit commercially available from GIBCO BRL Life Technologies Inc., Gettysburg, Md.
  • readings are taken for each well at 490 nm using a microwell reader.
  • a standard curve plot having the log of imazapyr concentration on the x-axis and the optical density reading at 490 nm (OD 490) on the Y-axis is used to determine unknown concentrations of imazapyr present in soil, water or plant samples from their OD 490 values.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides an imidazolinone hapten having the structural formula
Figure US20010020087A1-20010906-C00001
Further provided are an antigen and an enzyme conjugate which are prepared from the imidazolinone hapten. The haptens, antigens and enzyme conjugates provided are useful in immunoassays for determining the presence and concentration of an imidazolinone compound in the presence of one or more other imidazolinone compounds.

Description

    BACKGROUND OF THE INVENTION
  • The discovery, development and commercialization of the imidazolinone compounds has given new meaning to the term “weed control”; for within this series of compounds it has been found that some are broad-spectrum or total vegetation herbicides with activity in both herbaceous and woody plants while others are highly selective weed control agents useful in the presence of crops. The imidazolinones are best exemplified by the commercial compounds imazethapyr, imazaquin, imazamethabenz-methyl and imazapyr. [0001]
  • Imidazolinone compounds are used by farmers throughout the world to control undesirable plant species. In certain areas, several imidazolinone compounds are individually used to control weeds growing in the presence of different crops such as soybeans, corn, peanuts, wheat, barley, rye and sunflowers, among others. [0002]
  • Although imidazolinone compounds gradually degrade in the environment, residues remaining in the soil should be monitored so as to provide the most efficacious weed control while avoiding possible damage to follow crop plants. It is particularly important to monitor individual imidazolinone residues in those areas where several imidazolinones are used. [0003]
  • An enzyme-linked immunosorbent assay for the detection of imidazolinone compounds is described in allowed U.S. Pat. application Ser. No. 08/023,321, filed on Feb. 25, 1993. However, the polyclonal antibodies described in that patent application are not specific enough to determine the presence and concentration of an imidazolinone compound in the presence of one or more other imidazolinone compounds. [0004]
  • It is an object of the present invention to provide haptens and antigens and enzyme conjugates prepared therefrom which are useful in a method for determining the presence and concentration of an imidazolinone compound in the presence of one or more other imidazolinone compounds. [0005]
    • SUMMARY OF THE INVENTION
  • The present invention provides imidazolinone haptens and antigens and enzyme conjugates which are prepared from the imidazolinone haptens. [0006]
  • The antigens of the present invention are used to prepare imidazolinone specific monoclonal antibodies. Advantageously, certain of those monoclonal antibodies are used to determine the presence and concentration of an imidazolinone compound in the presence of one or more other imidazolinone compounds. [0007]
  • The enzyme conjugates of the present invention are used in a direct competition immunoassay to determine the presence and concentration of an imidazolinone compound. [0008]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides imidazolinone haptens that are used to prepare antigens which elicit imidazolinone specific antibody production in animals. [0009]
  • The imidazolinone haptens of the present invention have the structural formula [0010]
    Figure US20010020087A1-20010906-C00002
  • wherein [0011]
  • R is hydrogen or C[0012] 1-C4alkyl;
  • R[0013] 1 is C1-C4alkyl;
  • R[0014] 2 is C1-C4alkyl or C3-C6cycloalkyl; and when R1 and R2 are taken together with the carbon atom to which they are attached they may represent C3-C6cycloalkyl optionally substituted with methyl;
  • Y and Z are each independently hydrogen, halogen, C[0015] 1-C6-alkyl, C1-C4alkoxyalkyl, C1-C4hydroxyalkyl, C1-C4alkoxy, C1-C4alkylthio, phenoxy, C1-C4halo-alkyl, nitro, cyano, C1-C4alkylamino, di(C1-C4alkyl)amino, C1-C4alkylsulfonyl or phenyl optionally substituted with one C1-C4alkyl group, C1-C4alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH2)n-, where n is an integer of 3 or 4; or
    Figure US20010020087A1-20010906-C00003
  • where R[0016] 3, R4, R5 and R6 are each independently hydrogen, halogen, C1-C4alkyl or C1-C4alkoxy;
  • A is N or CH; [0017]
  • W is C[0018] 3-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C[0019] 3-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C[0020] 3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom; and
  • W[0021] 1 is Cl-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C[0022] 2-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C[0023] 3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom.
  • Preferred formula I and II haptens are those wherein [0024]
  • R is hydrogen or methyl; [0025]
  • R[0026] 1 is methyl;
  • R[0027] 2 is isopropyl;
  • Y is hydrogen, C[0028] 1-C4alkyl or C1-C4alkoxyalkyl;
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—; [0029]
  • A is N or CH; [0030]
  • W is C[0031] 3-C12alkylene or C3-C12alkenylene; and
  • W[0032] 1 is C1-C12alkylene or C2-C12alkenylene.
  • More preferred formula I and II haptens which are used to prepare antigens which elicit imidazolinone specific antibody production in animals are those wherein [0033]
  • R is hydrogen or methyl; [0034]
  • R[0035] 1 is methyl;
  • R[0036] 2 is isopropyl;
  • Y is hydrogen, methyl, ethyl or methoxymethyl; [0037]
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—; [0038]
  • A is N; [0039]
  • W is C[0040] 3-C6alkylene or C3-C6alkenylene; and
  • W[0041] 1 is C1-C6alkylene or C2-C6alkenylene.
  • Imidazolinone haptens of the present invention which are particularly useful in the preparation of antigens include [0042]
  • 6-[5-ethyl-2- (4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]hexanoic acid; [0043]
  • 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imi-dazoline-1-valeric acid; [0044]
  • 4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]butyric acid; [0045]
  • 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-crotonic acid, (E)-; [0046]
  • 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetic acid; and [0047]
  • 4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-N-methylnicotinoamido]butyric acid, among others. [0048]
  • The antigens of the present invention which are prepared from the imidazolinone haptens described above and are useful in the production of imidazolinone specific antibodies in animals have the structural formula [0049]
    Figure US20010020087A1-20010906-C00004
  • wherein [0050]
  • R is hydrogen or C[0051] 1-C4alkyl;
  • R[0052] 1 is C1-C4alkyl;
  • R[0053] 2 is C1-C4alkyl or C3-C6cycloalkyl; and when R1 and R2 are taken together with the carbon atom to which they are attached they may represent C3-C6cycloalkyl optionally substituted with methyl;
  • Y and Z are each independently hydrogen, halogen, C[0054] 1-C6-alkyl, C1-C4alkoxyalkyl, C1-C4hydroxyalkyl, C1-C4alkoxy, C1-C4alkylthio, phenoxy, C1-C4halo-alkyl, nitro, cyano, C1-C4alkylamino, di(C1-C4alkylamino, C1-C4alkylsulfonyl or phenyl optionally substituted with one C1-C4alkyl group, C1-C4alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH2)n-, where n is an integer of 3 or 4; or
    Figure US20010020087A1-20010906-C00005
  • where R[0055] 3, R4, R5 and R6 are each independently hydrogen, halogen, C1-C4alkyl or C1-C4alkoxy;
  • A is N or CH; [0056]
  • W is C[0057] 3-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C[0058] 3-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C[0059] 3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom;
  • W[0060] 1 is C1-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C[0061] 2-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C[0062] 3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom;
  • X is an integer from about 1 to 40; and [0063]
  • Q is a protein. [0064]
  • Proteins suitable for use in the antigens of this invention include cationized bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, bovine serum albumin, thyroglobulin, human serum albumin, fibrinogen and the like. [0065]
  • Preferred formula III and IV antigens of the present invention are those wherein [0066]
  • R is hydrogen or methyl; [0067]
  • R[0068] 1 is methyl;
  • R[0069] 2 is isopropyl;
  • Y is hydrogen, C[0070] 1-C4alkyl or C1-C4alkoxyalkyl;
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—; [0071]
  • A is N or CH; [0072]
  • W is C[0073] 3-C12alkylene or C3-C12alkenylene;
  • W[0074] 1 is C1-C12alkylene or C2-C12alkenylene;
  • X is an integer from about 1 to 40; and [0075]
  • Q is a protein. [0076]
  • More preferred formula III and IV antigens which elicit imidazolinone specific antibody production in animals are those wherein [0077]
  • R is hydrogen or methyl; [0078]
  • R[0079] 1 is methyl;
  • R[0080] 2 is isopropyl;
  • Y is hydrogen, methyl, ethyl or methoxymethyl; [0081]
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—; [0082]
  • A is N; [0083]
  • W is C[0084] 3-C6alkylene or C3-C6alkenylene;
  • W[0085] 1 is C1-C6alkylene or C2-C6alkenylene;
  • X is an integer from about 1 to 40; and [0086]
  • Q is a protein. [0087]
  • Antigens of the present invention which are especially useful in the production of imidazolinone specific antibodies are those having the following structural formula [0088]
    Figure US20010020087A1-20010906-C00006
  • wherein [0089]
  • X is an integer from about 1 to 40; [0090]
  • OVA is ovalbumin; and [0091]
  • Q is keyhole limpet hemocyanin or cationized bovine serum albumin. [0092]
  • The present invention further provides enzyme conjugates which are used in a direct competition immuno-assay to determine the presence of imidazolinone compounds in water, soil or plant samples. [0093]
  • The enzyme conjugates of the present invention have the structural formula [0094]
    Figure US20010020087A1-20010906-C00007
  • wherein [0095]
  • R is hydrogen or C[0096] 1-C4alkyl;
  • R[0097] 1 is C1-C4alkyl;
  • R[0098] 2 is C1-C4alkyl or C3-C6cycloalkyl; and when R1 and R2 are taken together with the carbon atom to which they are attached they may represent C3-C6cycloalkyl optionally substituted with methyl;
  • Y and Z are each independently hydrogen, halogen, C[0099] 1-C6-alkyl, C1-C4alkoxyalkyl, C1-C4hydroxyalkyl, C1-C4alkoxy, C1-C4alkylthio, phenoxy, C1-C4halo-alkyl, nitro, cyano, C1-C4alkylamino, di(C1-C4alkyl)amino, C1-C4alkylsulfonyl or phenyl optionally substituted with one C1-C4alkyl group, C1-C4alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH2)n-, where n is an integer of 3 or 4; or
    Figure US20010020087A1-20010906-C00008
  • where R[0100] 3, R4, R5 and R6 are each independently hydrogen, halogen, C1-C4alkyl or C1-C4alkoxy;
  • A is N or CH; [0101]
  • W is C[0102] 3-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C[0103] 3-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C[0104] 3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom;
  • W[0105] 1 is C1-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
  • C[0106] 2-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
  • C[0107] 3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom; and
  • E is an enzyme. [0108]
  • Enzymes suitable for use in the enzyme conjugates of the present invention include those that produce a color change when treated with a substrate. Preferred enzymes are alkaline phosphatase, horseradish peroxidase, urease, glucose oxidase and galactosidase. [0109]
  • Preferred formula VIII and IX enzyme conjugates are those wherein [0110]
  • R is hydrogen or methyl; [0111]
  • R[0112] 1 is methyl;
  • R[0113] 2 is isopropyl;
  • Y is hydrogen, C[0114] 1-C4alkyl or C1-C4alkoxyalkyl;
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—; [0115]
  • A is N or CH; [0116]
  • W is C[0117] 3-C12alkylene or C3-C12alkenylene;
  • W[0118] 1 is C1-C12alkylene or C2-C12alkenylene; and
  • E is an enzyme. [0119]
  • More preferred formula VIII and IX enzyme conjugates of the present invention are those wherein [0120]
  • R is hydrogen or methyl; [0121]
  • R[0122] 1 is methyl;
  • R[0123] 2 is isopropyl;
  • Y is hydrogen, methyl, ethyl or methoxymethyl; [0124]
  • Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—; [0125]
  • A is N; [0126]
  • W is C[0127] 3-C6alkylene or C3-C6alkenylene;
  • W[0128] 1 is C1-C6alkylene or C2-C6alkenylene; and
  • E is an enzyme. [0129]
  • One of the most preferred enzyme conjugates of this invention has the following structural formula [0130]
    Figure US20010020087A1-20010906-C00009
  • wherein [0131]
  • E is alkaline phosphatase. [0132]
  • The formula I haptens of the present invention may be prepared by reacting a compound having the structural formula XI [0133]
    Figure US20010020087A1-20010906-C00010
  • wherein Y, Z, A, R[0134] 1 and R2 are as described hereinabove with an amino acid compound having the structural formula XII
    Figure US20010020087A1-20010906-C00011
  • wherein R and W are as described hereinabove; and the acid addition salts thereof in the presence of a trialkylamine such as triethylamine and a polar solvent such as N,N-dimethylformamide to form a reaction mixture which is quenched with aqueous acid to form the desired formula I hapten. The above reaction scheme is shown in Flow Diagram I. [0135]
    Figure US20010020087A1-20010906-C00012
  • Alternatively, formula I haptens may be prepared by reacting a compound having the structural formula XI with an amino acid ester having the structural formula XIII [0136]
    Figure US20010020087A1-20010906-C00013
  • wherein [0137]
  • R and W are as described hereinabove; [0138]
  • R[0139] 7 is C1-C4alkyl; and
  • the acid addition salts thereof in the presence of a trialkylamine such as triethylamine and a polar solvent such as N,N-dimethylformamide to form a reaction mixture which is quenched with aqueous acid to obtain an ester compound having the structural formula XIV [0140]
    Figure US20010020087A1-20010906-C00014
  • wherein Y, Z, W, R[0141] 1, R2 and R7 are as described hereinabove, saponifying the formula XIV ester compound with aqueous base and quenching the saponification reaction mixture with acid to form the desired formula I hapten. The reaction scheme is shown in Flow Diagram II.
    Figure US20010020087A1-20010906-C00015
  • Formula II haptens may be prepared by reacting a compound having the structural formula XV [0142]
    Figure US20010020087A1-20010906-C00016
  • wherein Y, Z, A, R[0143] 1 and R2 are as described hereinabove with a metal hydride such as sodium hydride and a halo ester compound having the structural formula XVI
  • X1W1CO2R7  (XVI)
  • wherein [0144]
  • W[0145] 1 and R7 are as described hereinabove; and X1 is halogen to form a compound having the structural formula XVII
    Figure US20010020087A1-20010906-C00017
  • wherein Y, Z, W[0146] 1, R1, R2 and R7 are as described hereinabove, saponifying the formula XVII compound with aqueous base and quenching the saponification reaction mixture with acid to obtain the desired formula II hapten. The reaction scheme is shown in Flow Diagram
    Figure US20010020087A1-20010906-C00018
  • The antigens of the present invention may be prepared by reacting a hapten of the present invention with at least about one molar equivalent of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride to form an activated hapten and reacting the activated hapten with the amino groups of a protein to form the desired antigen. The above reaction scheme is shown in Flow Diagrams IV(a) and IV(b). [0147]
    Figure US20010020087A1-20010906-C00019
    Figure US20010020087A1-20010906-C00020
  • Similarly, the enzyme conjugates of the present invention may be prepared as shown below in Flow Diagrams V(a) and V(b). [0148]
    Figure US20010020087A1-20010906-C00021
    Figure US20010020087A1-20010906-C00022
  • The antigens of the present invention are used to elicit imidazolinone specific antibody production in animals. Several weeks after an animal is immunized with one or more antigens, the serum is harvested and the polyclonal antibodies present in the serum may be used in indirect or direct immunoassays to determine the presence and quantity of imidazolinone compounds in soil, water or plant samples. [0149]
  • Advantageously, it has been found that certain hybridomas, prepared by fusing a spleen cell from an animal immunized with an antigen of the present invention with a myeloma cell, produce monoclonal antibodies which are specific for one imidazolinone compound among others. Heretofore, imidazolinone antibodies were not specific enough to allow for the accurate determination of the presence and quantity of an imidazolinone compound in the presence of one or more other imidazolinone compounds. The methods used to prepare the polyclonal antibodies, hybridomas and monoclonal antibodies of the present invention are described in the examples. Also described in the examples are the indirect and direct immunoassay methods which are used to determine the presence and quantity of an imidazolinone compound present in a sample. [0150]
  • The imidazolinone compounds are represented by structural formula XVIII [0151]
    Figure US20010020087A1-20010906-C00023
  • wherein [0152]
  • Y, Z, A, R[0153] 1 and R2 are as described hereinabove; and
  • R[0154] 8 is hydrogen or C1-C4alkyl.
  • The polyclonal and monoclonal antibodies of this invention are especially useful in indirect and direct immunoassays to determine the presence and quantity of the following imidazolinone compounds: [0155]
  • 5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinic acid (imazethapyr); [0156]
  • 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-3-quinolinecarboxylic acid (imazaquin); [0157]
  • mixture of methyl 6-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-m-toluate and methyl 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-p-toluate (imazamethabenz-methyl); [0158]
  • 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinic acid (imazapyr); and [0159]
  • 2-(4-iscpropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methylnicotinic acid (imazamethapyr). [0160]
  • In order to facilitate a further understanding of the invention, the following examples are presented primarily for the purpose of illustrating more specific details thereof. The invention should not be deemed limited thereby except as defined in the claims. [0161]
    • EXAMPLE 1 Preparation of 4-[5-Ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-N-methylnicotinamidoz]-butyric acid
  • [0162]
    Figure US20010020087A1-20010906-C00024
  • A stirred solution of 7-ethyl-2-isopropyl-2-methyl-5H-imidazo[1′,2′:1,2]pyrrolo[3,4-b]pyridine-3(2H), 5-dione (5.47 g, 20.19 mmol) in anhydrous N,N-dimethylformamide is treated successively with 4-(methylamino)butyric acid hydrochloride (3.29 g, 21.2 mmol) and triethylamine (4.29 g, 42.39 mmol). The resulting mixture is stirred at room temperature under nitrogen for 2.5 hours. After this period, the reaction mixture is diluted with water, acidified with concentrated hydrochloric acid and extracted with ether. The organic extract is dried over magnesium sulfate, vacuum filtered through diatomaceous earth and concentrated in vacuo to give the title product as a white solid, mp 42-49° C. (dec.). [0163]
    • EXAMPLE 2 Preparation of Methyl 6-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]-hexanoate
  • [0164]
    Figure US20010020087A1-20010906-C00025
  • A stirred solution of 7-ethyl-2-isopropyl-2-methyl-5H-imidazo[1′,2′:1,2]pyrrolo[3,4-b]pyridine-3(2H),5-dione (7.25 g, 26.75 mmol) in anhydrous N,N-dimethylformamide is treated successively with methyl 6-aminocaproate hydrochloride (5.10 g, 28.1 mmol) and triethylamine (3.00 g, 29.6 mmol). The resulting mixture is stirred at room temperature under nitrogen for 20.5 hours. After this period, the reaction mixture is partitioned between water and ethyl acetate. The layers are separated, and the organic layer is washed with water dried over magnesium sulfate and vacuum filtered through diatomaceous earth. The filtrate is concentrated in vacuo to obtain a white solid. The solid is triturated with 1:1 ether/petroleum ether to give the title product as a white solid (7.40 g, 69%, mp 101-103° C.). [0165]
  • Using essentially the same procedure, but substituting methyl 4-aminobutyrate hydrochloride for 6-aminocaproate hydrochloride, methyl 4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]-butyrate is obtained as a white solid, mp 132-134° C. [0166]
    • EXAMPLE 3 Preparation of 6-[5-Ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamidolhexanoic acid
  • [0167]
    Figure US20010020087A1-20010906-C00026
  • A stirred solution of methyl 6-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]-hexanoate (5.14 g, 12.35 mmol) in tetrahydrofuran is treated with 2N sodium hydroxide (15 mL). The resulting mixture is stirred at room temperature for 24 hours. After this period, the reaction mixture is concentrated in vacuo to obtain a residue. The residue is cooled with an ice bath and acidified with concentrated hydrochloric acid. The resulting precipitate is isolated by vacuum filtration and washed with water to give the title product as a white solid, mp 76-81° C. [0168]
  • Using essentially the same procedure, but substituting methyl 4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]butyrate for 6-(5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-nicotinamido]hexanoate, 4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]butyric acid is obtained as a solid, mp 165-167° C. [0169]
    • EXAMPLE 4 Preparation of Ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-crotonate, (E)-
  • [0170]
    Figure US20010020087A1-20010906-C00027
  • A stirred suspension of sodium hydride (1.6 g, 53 mmol, 80% oil dispersion) in dry tetrahydrofuran is treated with a solution of 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline (10.24 g, 41.80 mmol) in dry tetrahydrofuran dropwise via addition funnel. After addition is complete and effervescence subsides, ethyl 4-bromocrotonate (12.9 g, 50.1 mmol, 75% technical grade) is added to the reaction mixture at once. The resulting mixture is stirred at room temperature under nitrogen for 19 hours. After this period, the reaction mixture is partitioned between water and ether. The layers are separated, and the organic layer is dried over magnesium sulfate, decolorized with activated charcoal, vacuum filtered through diatomaceous earth, and concentrated in vacuo to obtain a dark brown oil. The oil is purified by flash chromatography (2:1 hexanes/ethyl acetate eluent) to give the title product as a pale orange oil (3.78 g, 25%). [0171]
    • EXAMPLE 5 Preparation of 2- (5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-crotonic acid,
  • [0172]
    Figure US20010020087A1-20010906-C00028
  • A stirred solution of ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-crotonate, (E)- (1.16 g, 3.25 mmol) in 1:1 tetrahydrofuran/water is treated with sodium hydroxide (0.45 g, 11.3 mmol) at once. The resulting mixture is stirred at reflux for 1.5 hours, then at room temperature for 16.5 hours. After this period, the reaction mixture is diluted with water, and washed with ether. The aqueous layer is acidified with lN hydrochloric acid (15 mL), and extracted with ether. The organic extract is dried over sodium sulfate, decolorized with charcoal and vacuum filtered through diatomaceous earth. The filtrate is concentrated in vacuo to give the title product as a yellow solid, mp 53-58° C. [0173]
    • EXAMPLE 6 Preparation of Ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetate
  • [0174]
    Figure US20010020087A1-20010906-C00029
  • A stirred mixture of sodium hydride (0.45 g, 15 mmol, 80% oil dispersion) in anhydrous tetrahydrofuran is treated with a solution of 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline (3.30 g, 13.47 mmol) in anhydrous tetrahydrofuran dropwise over the course of 40 minutes. After addition is complete and the initial effervescence subsides, ethyl bromoacetate (2.30 g, 13.50 mmol) is added to the reaction mixture. After 24 hours stirring at room temperature under nitrogen, the reaction mixture is partitioned between water and ether. The layers are separated, and the organic layer is dried over magnesium sulfate, vacuum filtered through diatomaceous earth and concentrated in vacuo to obtain a residue. The residue is purified by flash chromatography (2:1 hexanes/ethyl acetate eluent) to give the title product as a pale yellow oil. [0175]
  • Using essentially the same procedure, but substituting ethyl 5-bromovalerate for ethyl bromoacetate, ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-valerate is obtained as a gum. [0176]
    • EXAMPLE 7 Preparation of 2-(5-Ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetic acid
  • [0177]
    Figure US20010020087A1-20010906-C00030
  • A stirred solution of ethyl 2-(5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetate (2.12 g, 6.41 mmol) in tetrahydrofuran is treated with 2N sodium hydroxide (8 mL). The resulting mixture is stirred at room temperature for 16 hours. After this period, the reaction mixture is concentrated in vacuo to obtain a residue. The residue is acidified with concentrated hydrochloric acid and then extracted with ether. The organic extract is dried over magnesium sulfate, vacuum filtered through diatomaceous earth and concentrated in vacuo to give the title product as a white solid, mp 134-136° C. [0178]
  • Using essentially the same procedure, but substituting ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-valerate for ethyl 2-(5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetate, 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-valeric acid is obtained as a gum. [0179]
    • EXAMPLE 8
  • Antigen preparation [0180]
  • The hapten prepared in Example 3, 6-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl) nicotin-amido]hexanoic acid (16.5 mg, 0.04 mmol), is dissolved in 100 μL of tetrahydrofuran and diluted to 0.5 mL with an alkaline aqueous buffer (pH 7.2-7.6). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.8 mg, 0.04 mmol) is added to the hapten solution to generate activated carboxyl groups on the hapten. The mixture containing the activated hapten is added to a solution of keyhole limpet hemocyanin (KLH, 10 mg, 22 nmol) in alkaline aqueous buffer (pH 7.2-7.6). The final molar ratio of hapten to total protein amino groups is greater than 100 to 1. The reaction mixture is stirred for 2 hours at room temperature and passed through molecular sieving columns to remove excess reagents. The antigen fraction is filtered through a 0.22 μ filter and stored at 4° C. Flow Diagram VI illustrates the above reactions. [0181]
    Figure US20010020087A1-20010906-C00031
  • wherein X is an integer of 1 to 40; and [0182]
  • KLH is keyhole limpet hemocyanin. [0183]
  • Using essentially the same procedure, the following antigens are prepared: [0184]
    Figure US20010020087A1-20010906-C00032
  • wherein [0185]
  • X is an integer from about 1 to 40; [0186]
  • cBSA is cationized bovine serum albumin; [0187]
  • OVA is ovalbumin; and [0188]
  • KLH is keyhole limpet hemocyanin. [0189]
    • EXAMPLE 9
  • Immunization of mice [0190]
  • Pairs of mice of the Swiss Webster and Biozzi strains are immunized with antigens A, B, D and E, prepared in Example 8. The initial doses consist of 50 μg of antigen in 0.1 mL of physiological saline and one mouse dose (about 50 μg) of Ribi adjuvant (“MPL+TDM Emulsion,” Ribi Immunochem Research, Hamilton, Mont.). Booster doses are given 7 and 22 days after the first dose and consist of 25 μg of antigen in saline with Ribi adjuvant. Immunizations are subcutaneous, in 3 or 4 sites on the back of the mouse. Sera are taken on the twenty-ninth day after the first injection. Titers are determined by indirect enzyme immunoassay and then analyzed for ability to bind free imidazolinones in an indirect competition enzyme immunoassay as described below. [0191]
  • Enzyme immunoassays [0192]
  • An indirect enzyme immunoassay is used to screen for the production of anti-imidazolinone antibodies in the serum of the immunized mice and in cell fusion cultures. The method used is essentially the same as the method described by Voller, et al (Manual of Clinical Immunology, eds. N. Rose Friedman, H., pp. 506-512, 1976). For the indirect enzyme immunoassays, an antigen is adsorbed onto polystyrene flat bottom wells in 0.1 M Na[0193] 2CO3 buffer pH 9.6. Excess unbound material is washed away with buffer (PBS, containing 0.1 M NaH2PO4 -Na2HPO4 pH 7.6 with 0.05% Tween®20 and 0.02% NaN3). A 0.05% gelatin solution prepared in PBS is used to block the sites unoccupied by the antigen to prevent non-specific binding of reagents. Antibody from serum or culture are added into the wells for binding to the bound antigen. The wells are washed and the amount of bound anitbody is determined by adding alkaline phosphatase-conjugated goat anti-mouse IgG (Boehringer) to the wells followed by the addition of a p-nitrophenyl phosphate solution for color development. The color intensity is determined spectrophotometrically and is used to determine the titers.
  • In the indirect competition enzyme immunoassay, sera or cell fusion cultures which exhibit high titers are added to wells containing bound antigen in the presence of an imidazolinone solution. The bound antigen and imidazolinone compound compete for the antibody molecules. The wells are then washed and the color is developed as described above. In this assay, the color is inversely proportional to the amount of imidazolinone compound. In practice, standard curves are generated with known amounts of an imidazolinone compound and amounts present in test samples are calculated by interpolation. [0194]
    • EXAMPLE 10
  • Preparation of hybridomas [0195]
  • The best responding Swiss Webster mouse is “hyperimmunized” by intravenous injection of 50 μg of antigen in saline, 4 days prior to cell fusion which is about 60 days after the first immunization. The hybridomas are prepared by fusing spleen cells from the mouse with P3X63AG8.653 myeloma cells by electrofusion. The reagent buffers and cell culture media used are essentially the same as described by B. Forghani and A. E. Karu, Virology LabFAX, eds. DR Harper, pp. 187-214, Oxford: Bios Scientific Publishers Ltd., 1993. The electrofusion is performed as described by A. E. Karu et al, Journal of Agricultural and Food Chemistry, 42, pp. 301-309, 1994. [0196]
  • Four hundred hybridoma colonies are screened in 4 groups over a 12 day period. Eighty-four of the hybridoma colonies react with the antigens shown below. [0197]
    Figure US20010020087A1-20010906-C00033
  • wherein X is an integer from about 10 to 40. [0198]
  • and [0199]
    Figure US20010020087A1-20010906-C00034
  • wherein X is an integer from about 1 to 40. [0200]
  • Only one monoclonal antibody generated from one of the hybridoma colonies specifically binds antigen H and 83 monoclonal antibodies from culture supernatants react with antigen G. The cell lines are expanded to 24 well culture dishes. Seventeen of the 24 well cultures test positive in a second indirect enzyme immunoassay and 11 of these competitively bind imidazolinone compounds in competition enzyme immunoassays. Cultures that produce nonspecific, adventitious-binding antibodies are eliminated by enzyme immunoassay on plates coated with kehole limpet hemocyanin. Table I lists all of the monoclonal antibodies (MAbs) that remain after the secondary screening. [0201]
    TABLE I
    MAb
    1A5.5
    2C6.5
    3A2.2
    1D2.6
    1B5.6
    1B5.7
    3A5.1
    4A6
    • EXAMPLE 11
  • Specifirities of the monoclonal antibodies in competition enzyme immunoassas [0202]
  • Indirect competition enzyme immunoassays for several imidazolinone compounds, using various monoclonal antibodies and antigens, are conducted according to the procedure described in Example 9. Table II summarizes the half-maximal dose responses. Antigens G and H are as described in Example 10 and Antigen I is shown below. [0203]
  • As can be seen from the data in Table II, monoclonal antibodies 1A5.5 and 1D2.6 bind imazethapyr with greater affinity when compared to the other imidazolinone compounds. [0204]
    Figure US20010020087A1-20010906-C00035
  • wherein X is an integer from about 10 to 40. [0205]
    TABLE II
    Competitive Binding of Imidazolinones in Indirect Enzyme Immunoassays
    Values are I50 (half-maximal inhibition) in ppb (ng/mL)
    Monoclonal Antibody
    1A5.5 1D2.6 2C6.5 3A2.2 3A5.1
    Imidazolinone Coating Antigen
    Compound H I G I G I G I G
    zethapyr 60 20 >10,000 15 13 21 34 220 >1,000
    zapyr 500 >1,000 >10,000 NC NC 331 290 >5,000 NC
    zaquin >1,000 2,000 >10,000 NC NC 3 5 800 NC
    zamethabenz-methyl 500 105 >10,000 NC NC 356 322 90 400
    zamethapyr 100 250 >10,000 204 171 27 31 340 >1,000
    • EXAMPLE 12
  • Preparation of an enzyme conjugate [0206]
  • A solution of 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (11.7 mg, 0.06 mmol) and N-hydroxy-5 succinimide ([0207] 13.1 mg, 0.06 mmol) in 1:1 N,N-dimethylformamide/water is added to a solution of 6-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotin-amido]hexanoic acid (24.7 mg, 0.06 mmol) in N,N-dimethylformamide. After stirring for 3.5 hours, the reaction mixture is slowly added to an alkaline phosphatase solution in 0.05 M sodium borate buffer pH 7.5 with 0.9% NaCl. The resultant mixture is stirred at 4° C. for 18 hours and passed through an agarose column to give an enzyme conjugate having the structural formula shown below.
    Figure US20010020087A1-20010906-C00036
  • wherein E is alkaline phosphatase. [0208]
    • EXAMPLE 13
  • Direct competition enzyme immunoassay The monoclonal antibody 3A2.2 prepared in Example 10 and the enzyme conjugate prepared in Example 12 are used to establish a direct competition enzyme immunoassay method for the determination of the concentration of imazapyr in samples. A constant amount of the monoclonal antibody 3A2.2 is adsorbed onto polystyrene plate wells through an affinity purified goat anti-mouse immunoglobulin which is previously adsorbed onto the polystyrene plate wells. The wells are washed with buffer (PBS, containing 0.01 M NaH[0209] 2PO4-Na2HPO4 pH 7.6 with 0.05% Tween®20 and 0.02% NaN3) and blocked with a 0.05% gelatin solution prepared in PBS. Standard solutions having concentrations of imazapyr from 0 to 5,000 ng/mL are added to the blocked wells followed by the addition of the aforementioned enzyme conjugate.
  • After several minutes, the wells are washed and the color is developed by adding BRL alkaline phosphatase substrate amplification kit (commercially available from GIBCO BRL Life Technologies Inc., Gettysburg, Md.). After several minutes, readings are taken for each well at 490 nm using a microwell reader. [0210]
  • A standard curve plot having the log of imazapyr concentration on the x-axis and the optical density reading at 490 nm (OD 490) on the Y-axis is used to determine unknown concentrations of imazapyr present in soil, water or plant samples from their OD 490 values. [0211]
  • The OD 490 readings for 6 imazapyr standard solutions and a solvent blank are obtained from a direct enzyme immunoassay experiment run in triplicate. The means and standard deviations are calculated and are summarized in Table III. The standard curve obtained by plotting the mean OD 490 reading versus the logarithm of the standard imazapyr concentration is used to determine unknown imazapyr concentrations from about 0.5 ng/mL to 500 ng/mL. [0212]
    TABLE III
    Imazapyr
    Concentration OD 490 Standard
    (ng/mL) Reading Deviation
    0.00 2.616 0.125
    0.05 2.671 0.096
    0.50 2.507 0.094
    5.0 1.893 0.078
    50 0.801 0.033
    500 0.474 0.012
    5,000 0.446 0.001

Claims (31)

What is claimed is:
1. An imidazolinone hapten having the structural formula
Figure US20010020087A1-20010906-C00037
wherein
R is hydrogen or C1-C4alkyl;
R1 is C1-C4alkyl;
R2 is C1-C4alkyl or C3-C6cycloalkyl; and when R1 and R2 are taken together with the carbon atom to which they are attached they may represent C3-C6cycloalkyl optionally substituted with methyl;
Y and Z are each independently hydrogen, halogen, C1-C6-alkyl, C1-C4alkoxyalkyl, C1-C4hydroxyalkyl, C1-C4alkoxy, C1-C4alkylthio, phenoxy, C1-C4halo-alkyl, nitro, cyano, C1-C4alkylamino, di(C1-C4alkyl)amino, C1-C4alkylsulfonyl or phenyl optionally substituted with one C1-C4alkyl group, C1-C4alkoxy group or halogen atom; and when taken together, Y and Z may form a ring in which YZ are represented by the structure: -(CH2)n-, where n is an integer of 3 or 4; or
Figure US20010020087A1-20010906-C00038
where R3, R4, R5 and R6 are each independently hydrogen, halogen, C1-C4alkyl or C1-C4alkoxy;
A is N or CH;
W is C3-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
C3-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
C3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom; and
W1 is C1-C12alkylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom,
C2-C12alkenylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom, or
C3-C12alkynylene optionally substituted with one or two C1-C3alkyl groups, C1-C3alkoxy groups, oxo groups or halogen atoms, and optionally interrupted by one oxygen or sulfur atom.
2. The imidazolinone hapten according to
claim 1
 wherein
R is hydrogen or methyl;
R1 is methyl;
R2 is isopropyl;
Y is hydrogen, C1-C4alkyl or C1-C4alkoxyalkyl;
Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—;
A is N or CH;
W is C3-C12alkylene or C3-C12alkenylene; and
W1 is C1-C12alkylene or C2-C12alkenylene.
3. The imidazolinone hapten according to
claim 2
 wherein
R is hydrogen or methyl;
R1 is methyl;
R2 is isopropyl;
Y is hydrogen, methyl, ethyl or methoxymethyl;
Z is hydrogen; and when taken together, Y and Z may form a ring in which YZ is represented by the structure: —CH═CH—CH═CH—;
A is N;
W is C3-C6alkylene or C3-C6alkenylene; and
W1 is C1-C6alkylene or C2-C6alkenylene.
4. The imidazolinone hapten according to
claim 3
,
6-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]hexanoic acid.
5. The imidazolinone hapten according to
claim 3
,
2-(5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-valeric acid.
6. The imidazolinone hapten according to
claim 3
,
4-[5-ethyl-2- (4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]butyric acid.
7. The imidazolinone hapten according to
claim 3
,
2-(5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-crotonic acid, (E)-.
8. The imidazolinone hapten according to
claim 3
,
2-(5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetic acid.
9. The imidazolinone hapten according to
claim 3
,
4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-N-methylnicotinamido]butyric acid.
10. An antigen having the structural formula
Figure US20010020087A1-20010906-C00039
wherein
R, R1, R2, Y, Z, A, W and W1 are as described in
claim 1
;
X is an integer from about 1 to 40; and
Q is a protein.
11. The antigen according to
claim 10
 wherein the protein is selected from the group consisting of cationized bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, bovin serum albumin, thyroglobulin, human serum albumin and fibrinogen.
12. The antigen according to
claim 10
 wherein R, R1, R2, Y, Z, A, is and W1 are as described in
claim 2
.
13. The antigen according to
claim 12
 wherein R, R1, R2, Y, Z, A, W and W1 are as described in
claim 3
.
14. The antigen according to
claim 13
 having the structural formula
Figure US20010020087A1-20010906-C00040
wherein
X is an integer from about 1 to 40; and
KLH is keyhole limpet hemocyanin.
15. The antigen according to
claim 13
 having the structural formula
Figure US20010020087A1-20010906-C00041
wherein
X is an integer from about 1 to 40; and
cBSA is cationized bovine serum albumin.
16. The antigen according to
claim 13
 having the structural formula
Figure US20010020087A1-20010906-C00042
wherein
X is an integer from about 1 to 40; and
KLH is keyhole limpet hemocyanin.
17. The antigen according to
claim 13
 having the structural formula
Figure US20010020087A1-20010906-C00043
wherein
X is an integer from about 1 to 40; and
cBSA is cationized bovine serum albumin.
18. The antigen according to
claim 13
 having the structural formula
Figure US20010020087A1-20010906-C00044
wherein
X is an integer from about 1 to 40; and
OVA is ovalbumin
19. An enzyme conjugate having the structural formula
Figure US20010020087A1-20010906-C00045
wherein
R, R1, R2, Y, Z, A, W and W1 are as described in
claim 1
;
and E is an enzyme.
20. The enzyme conjugate according to
claim 19
 wherein the enzyme is selected from the group consisting of alkaline phosphatase, horseradish peroxidase, urease, glucose oxidase and galactosidase.
21. The enzyme conjugate according to
claim 19
 wherein R, R1, R2, Y, Z, A, W and W1 are as described in
claim 2
.
22. The enzyme conjugate according to
claim 21
 wherein R, R1, R2, Y, Z, A, W and W1 are as described in
claim 3
.
23. The enzyme conjugate according to
claim 22
 having the structural formula
Figure US20010020087A1-20010906-C00046
wherein E is alkaline phosphatase.
24. A compound having the structural formula
Figure US20010020087A1-20010906-C00047
wherein
R, R1, R2, Y, Z, A, W and W1 are as described in
claim 1
;
and R7 is C1-C4alkyl.
25. The compound according to
claim 24
 wherein R, R1, R2, Y, Z, A, W and W1 are as described in
claim 2
.
26. The compound according to
claim 25
 wherein R, R1, R2, Y, Z, A, W and W1 are as described in
claim 3
; and
R7 is methyl or ethyl.
27. The compound according to
claim 26
, methyl 6-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]hexanoate.
28. The compound according to
claim 26
, methyl 4-[5-ethyl-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinamido]butyrate.
29. The compound according to
claim 26
, ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-crotonate, (E)-.
30. The compound according to
claim 26
, ethyl 2-(5-ethyl-2-pyridyl) -4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-acetate.
31. The compound according to
claim 26
, ethyl 2-(5-ethyl-2-pyridyl)-4-isopropyl-4-methyl-5-oxo-2-imidazoline-1-valerate.
US09/805,760 1994-11-03 2001-03-13 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom Abandoned US20010020087A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/805,760 US20010020087A1 (en) 1994-11-03 2001-03-13 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/333,826 US5693658A (en) 1994-11-03 1994-11-03 Imidazolinones
US08/782,698 US6407217B1 (en) 1994-11-03 1997-01-16 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom
US09/805,760 US20010020087A1 (en) 1994-11-03 2001-03-13 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/782,698 Division US6407217B1 (en) 1994-11-03 1997-01-16 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom

Publications (1)

Publication Number Publication Date
US20010020087A1 true US20010020087A1 (en) 2001-09-06

Family

ID=23304412

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/333,826 Expired - Lifetime US5693658A (en) 1994-11-03 1994-11-03 Imidazolinones
US08/782,698 Expired - Fee Related US6407217B1 (en) 1994-11-03 1997-01-16 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom
US08/782,699 Expired - Fee Related US5808079A (en) 1994-11-03 1997-01-16 Imidazolinone haptens
US09/805,760 Abandoned US20010020087A1 (en) 1994-11-03 2001-03-13 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/333,826 Expired - Lifetime US5693658A (en) 1994-11-03 1994-11-03 Imidazolinones
US08/782,698 Expired - Fee Related US6407217B1 (en) 1994-11-03 1997-01-16 Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom
US08/782,699 Expired - Fee Related US5808079A (en) 1994-11-03 1997-01-16 Imidazolinone haptens

Country Status (4)

Country Link
US (4) US5693658A (en)
EP (1) EP0710660A1 (en)
AR (1) AR002242A1 (en)
BR (1) BR9505049A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043336A3 (en) * 1999-03-29 2000-12-20 The Regents of the University of California Stereospecific antibodies for imidazolinone herbicides
US7117435B1 (en) 2000-06-21 2006-10-03 Microsoft Corporation Spreadsheet fields in text

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798619A (en) * 1980-06-02 1989-01-17 American Cyanamid Co. 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents
US5342771A (en) * 1990-12-03 1994-08-30 American Cyanamid Company Functionalized imidazolinone haptens and protein conjugates thereof useful in assays for the detection of imidazolinone herbicides

Also Published As

Publication number Publication date
US5808079A (en) 1998-09-15
EP0710660A1 (en) 1996-05-08
US5693658A (en) 1997-12-02
US6407217B1 (en) 2002-06-18
BR9505049A (en) 1997-10-21
AR002242A1 (en) 1998-03-11

Similar Documents

Publication Publication Date Title
US5532137A (en) Anti-FR-900506 substance antibodies and highly-sensitive enzyme immunoassay method
US7148029B2 (en) Immunoassay for neonicotinyl insecticides
DE69121844T2 (en) Immunoassay for cyclosporin
NO160103B (en) IODTYRONIN NIMMUNOGEN CONJUGATE AND IODTYRON INGREDIENTS FOR PREPARING THE IODTYRONIN NIMMUNOGEN CONJUGATE.
GB1567768A (en) N-derivatives of carbamazephine
JP3884586B2 (en) Imidacloprid hapten compound, antibody and assay
JPH08510231A (en) Methods, agents and kits for detecting organophosphorus compounds
US6407217B1 (en) Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom
CZ202693A3 (en) Immunoanalysis of isothiazolones
US5264556A (en) Monoclonal antibodies for measuring okadaic acid
JP2000191699A (en) Monoclonal antibody to be specifically reacted with coplanar pcb substantially not reducing antigen recognition characteristic even in 50 (v/v)% aqueous solution of organic solvent, and its measurement
EP0690071B1 (en) Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase
HUT65371A (en) Immunological diagnostic process
US5342771A (en) Functionalized imidazolinone haptens and protein conjugates thereof useful in assays for the detection of imidazolinone herbicides
JP3950600B2 (en) Fenitrothion hapten compound, antibody and assay
KR100876435B1 (en) Antibody and hapten-protein conjugate utilized in an enzyme-linked immunosorbent assay (ELISA) for insecticide bistrifluron residues
US6465194B2 (en) Monoclonal antibodies to 4,4′-dinitrocarbanilide and a method for analyzing for the drug nicarbazin
JP3842919B2 (en) Chlorfenapyr hapten compound, antibody and assay
JP3026942B2 (en) Hapten compounds of diazinon, antibodies and methods of measurement
JP2001039953A (en) Hapten compound of pyriminobac-methyl, antibody and method for measurement
JPH0543358B2 (en)
JP4639348B2 (en) Antibody specific to halogenated benzylate compound, method for producing the antibody, and immunological assay
KR0141313B1 (en) Novel monoclonal antibody against human blood apolipoprotein a-1 and recombinat hybridoma cell line for thd production thereof
KR20000002227A (en) Novel monoclonic antibodies for human plasma apolipoprotein and hybridoma strains which produce them
JP2001255324A (en) Antibodies to fusalide and method for measurement

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION